(Q36981678)

17 August 2017

1 reference

title

L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer (English)

1 reference

17 August 2017

1 reference

Randeep Sangha

1

1 reference

17 August 2017

Scott North

series ordinal

2

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Expert Opinion on Biological Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

7

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1723-1730

1 reference

17 August 2017

cites work

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Prostate cancer screening: what we know and what we need to know.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Natural history of progression after PSA elevation following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Determination of apical membrane polarity in mammary epithelial cell cultures: The role of cell-cell, cell-substratum, and membrane-cytoskeleton interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Mucins: structure, function, and associations with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

What makes MUC1 a tumor antigen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

L-BLP25: a peptide vaccine strategy in non small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

MUC1 mediates transendothelial migration in vitro by ligating endothelial cell ICAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.11.1723

10.1517/14712598.7.11.1723

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference